Spain's Oryzon shares soar after US Cancer Institute agrees to test new
drug
Send a link to a friend
 [July 19, 2022]
MADRID (Reuters) - Shares of Spanish
biopharma company Oryzon Genomics soared on Tuesday after the U.S.
National Cancer Institute agreed to test a new anti-tumor drug, the
company said in a statement.
The collaboration will assess the safety and efficacy of iadademstat,
the name of Oryzon's drug, in cancer patients with different
hematological and solid tumors.
[to top of second column]
|
 "This research and development
agreement with the NCI is a strong validation of iadademstat,
probably the most potent and selective LSD1 inhibitor currently in
clinical development," Oryzon CEO Carlos Buesa said.
Stocks in the Barcelona-based company were up 17.2%
to 2.76 euros following the announcement on Tuesday morning.
(Reporting by Christina Thykjaer, Editing by Inti Landauro, Emma
Pinedo and Ed Osmond)
[© 2022 Thomson Reuters. All rights
reserved.] This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
